scholarly journals Is Cardiac Shock Wave Therapy an Option for the Treatment of Myocardial Ischemia in Patients with Refractory Angina?

Author(s):  
Francesco Nudi ◽  
Fabrizio Tomai
2009 ◽  
Vol 2009 ◽  
pp. 1-3 ◽  
Author(s):  
Christian Prinz ◽  
Oliver Lindner ◽  
Thomas Bitter ◽  
Detlef Hering ◽  
Wolfgang Burchert ◽  
...  

Different therapeutic options are being used for chronic coronary artery disease (CAD). We report about a 51-year-old female with CAD and refractory angina pectoris despite maximally tolerated medical therapy and after both percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). The patient received cardiac shock wave therapy (CSWT) over a period of 6 month. There was no arrhythmia during or after treatment; enzyme levels were normal at all times. PET imaging showed a substantial improvement of myocardial stress perfusion. Since the patient reported that she now was fully capable to deal with her everyday life, further treatment options were postponed. Our case report suggests that ultrasound-guided CSWT is able to improve symptoms and perfusion in ischemic myocardium.


2021 ◽  
Vol 8 ◽  
Author(s):  
Liu Weijing ◽  
Fan Ximin ◽  
Shen Jianying ◽  
Zhu Mengyun ◽  
Fan Xuehua ◽  
...  

Background: Cardiac shock wave therapy (CSWT) is a non-invasive new option for the treatment of chronic refractory angina pectoris (CRAP). This study aimed to evaluate the safety and efficiency of CSWT in the treatment of CRAP.Methods: Eighty-seven patients with CRAP were randomly allocated into CWST group (n = 46) and Control group (n = 41). Canadian Cardiovascular Society (CCS) grade of angina pectoris, Seattle Angina Questionnaire (SAQ) score, 6-min walk test (6MWT), weekly dosage of nitroglycerin, and myocardial perfusion on D-SPECT were determined at baseline and during the follow-up period. Adverse events were also evaluated.Results: CSWT was well-tolerated in the CSWT patients. CSWT significantly improved the CCS grade, SAQ score, and 6MWT (p < 0.05). Imaging examinations showed that the ischemic area was reduced after CSWT. However, no significant changes were observed in the Control group.Conclusions: CSWT may improve the myocardial perfusion and reduce clinical symptoms without increasing adverse effects in CRAP patients. It provides a non-invasive and safe clinical therapy for CRAP patients.Clinical Trial registration:www.ClinicalTrials.gov, identifier: NCT03398096.


Sign in / Sign up

Export Citation Format

Share Document